AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1872596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine + ascorbic acid
Number of subjects: 60
Study 1872596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine + iron
Number of subjects: 60
Study 1872596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine + riboflavin
Number of subjects: 60
Study 1872596 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplements
Number of subjects: 60
Study 6315982 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of guar gum
Number of subjects: 11
Study 6315982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31144427 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin in combination with metformin
Number of subjects: 0
Study 31144427 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29564872 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% omega-ceramides, hydrophilic sugars, 5% niacinamide cream applied twice daily (group A)
Number of subjects: 27
Study 29564872 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied twice daily (group B)
Number of subjects: 27
Study 27387214 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency (BP RF) applied to 36 patients
Number of subjects: 71
Study 27387214 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar radiofrequency (MP RF) applied to 35 patients
Number of subjects: 71
Study 27387214 — intervention group
Group type: COMPARATOR
Intervention: Bipolar radiofrequency (BP RF)
Number of subjects: 71
Study 27387214 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar radiofrequency (MP RF)
Number of subjects: 71
Study 24798767 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg zinc supplementation for 24 weeks
Number of subjects: 52
Study 24798767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 22752960 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized working memory training (adaptive)
Number of subjects: 26
Study 22752960 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition (nonadaptive)
Number of subjects: 26
Study 20362710 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of EPA + DHA and 2 g of ALA
Number of subjects: 4837
Study 20362710 — intervention group
Group type: COMPARATOR
Intervention: Placebo (margarine spread without EPA + DHA and ALA)
Number of subjects: 4837
Study 16865379 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin
Number of subjects: 40
Study 16865379 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 40
Study 16767436 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-B (0.3 g/kg protein before RT + placebo after RT)
Number of subjects: 29
Study 16767436 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-A (placebo before + protein after RT)
Number of subjects: 29
Study 16767436 — intervention group
Group type: COMPARATOR
Intervention: PLA (placebo before and after RT)
Number of subjects: 29
Study 16767436 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (PRO-B, PRO-A, PLA)
Number of subjects: 29
Study 10891984 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-appearing white matter (NAWM) in patients with MS
Number of subjects: 35
Study 10891984 — intervention group
Group type: EXPERIMENTAL
Intervention: MS lesions (173 identified lesions)
Number of subjects: 35
Study 10891984 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancing lesions (22 lesions)
Number of subjects: 35
Study 10891984 — intervention group
Group type: EXPERIMENTAL
Intervention: T1-hypointense lesions (60 lesions)
Number of subjects: 35
Study 10891984 — intervention group
Group type: COMPARATOR
Intervention: NAWM
Number of subjects: 35
Study 8847861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 8847861 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg diltiazem OD
Number of subjects: 138
Study 8847861 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg diltiazem OD
Number of subjects: 138
Study 8847861 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg diltiazem OD
Number of subjects: 138
Study 8847861 — intervention group
Group type: EXPERIMENTAL
Intervention: 420 mg diltiazem OD
Number of subjects: 138
Study 1562095 — intervention group
Group type: EXPERIMENTAL
Intervention: SAT-1 (Edwards)
Number of subjects: 80
Study 1562095 — intervention group
Group type: EXPERIMENTAL
Intervention: SAT-2 (Baxter, Edwards Division)
Number of subjects: 80
Study 1562095 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemopro2 (Spectramed)
Number of subjects: 80
Study 1562095 — intervention group
Group type: EXPERIMENTAL
Intervention: Oximetrix 3 (Abbott)
Number of subjects: 80
Study 6320945 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid rich oil (fish oil)
Number of subjects: 0
Study 6320945 — intervention group
Group type: COMPARATOR
Intervention: Eicosapentaenoic acid poor oil (corn/olive oil)
Number of subjects: 0
Study 30581138 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical activity and fall prevention intervention (one physiotherapist visit, fortnightly telephone-based health coaching, a pedometer, tailored fall prevention advice, and a fall prevention brochure)
Number of subjects: 131
Study 30581138 — intervention group
Group type: COMPARATOR
Intervention: Control group (received the same fall prevention brochure)
Number of subjects: 131
Study 30581138 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical activity and fall prevention intervention
Number of subjects: 131
Study 30581138 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 131
Study 30165465 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy (eAT; N = 181)
Number of subjects: 354
Study 30165465 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting with supportive care (WWSC; N = 173)
Number of subjects: 354
Study 27042750 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH (rhGH) treatment for 2 years
Number of subjects: 57
Study 27042750 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH (rhGH) treatment with 25(OH)D above the 50th percentile
Number of subjects: 57
Study 27042750 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH (rhGH) treatment with 25(OH)D below the 50th percentile
Number of subjects: 57
Study 24201089 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening walking group (30 min/day or more on at least 5 days/week for 12 weeks)
Number of subjects: 330
Study 24201089 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning walking group (30 min/day or more on at least 5 days/week for 12 weeks)
Number of subjects: 330
Study 24201089 — intervention group
Group type: COMPARATOR
Intervention: Control group (no walking intervention)
Number of subjects: 330
Study 22454414 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² IV over 1 hour for 21 days plus prednisone 5 mg orally twice per day plus bevacizumab 15 mg/kg IV every 3 weeks (DP + B)
Number of subjects: 1050
Study 22454414 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m² IV over 1 hour for 21 days plus prednisone 5 mg orally twice per day (DP)
Number of subjects: 1050
Study 20064492 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued gait training with external rhythmical cues (auditory, visual, and somatosensory) for 3 weeks
Number of subjects: 153
Study 19226894 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Huatuojiaji points
Number of subjects: 56
Study 19226894 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 56
Study 16152868 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 30
Study 16152868 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study 12490735 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg monthly by intramuscular injection
Number of subjects: 851
Study 12490735 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole 1 mg daily
Number of subjects: 851
Study 12490735 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant and Anastrozole
Number of subjects: 851
Study 12490735 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 851
Study 12490735 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 851
Study 10718489 — intervention group
Group type: EXPERIMENTAL
Intervention: Oophorectomy plus tamoxifen
Number of subjects: 482
Study 10718489 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 482
Study 8967879 — intervention group
Group type: EXPERIMENTAL
Intervention: PE‐PEUG (new polyurethane vascular access graft)
Number of subjects: 52
Study 8967879 — intervention group
Group type: COMPARATOR
Intervention: E‐PTFEG (expanded polytetrafluoroethylene graft)
Number of subjects: 52
Study 1938279 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 14
Study 1938279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6749827 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 23
Study 6749827 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 23
Study 6749827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 6749827 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 23
Study 31969301 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 1% gel
Number of subjects: 0
Study 31969301 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 1% mouthwash
Number of subjects: 0
Study 31969301 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 28360116 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8-mg folic acid and 10-mg enalapril
Number of subjects: 20424
Study 28360116 — intervention group
Group type: COMPARATOR
Intervention: 10-mg enalapril only
Number of subjects: 20424
Study 26616535 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality intervention (Second Life)
Number of subjects: 202
Study 26616535 — intervention group
Group type: COMPARATOR
Intervention: Phone conference call intervention
Number of subjects: 202
Study 24038736 — intervention group
Group type: EXPERIMENTAL
Intervention: No tumor spill
Number of subjects: 499
Study 24038736 — intervention group
Group type: COMPARATOR
Intervention: Tumor spill
Number of subjects: 499
Study 22004512 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion at 2 kcal/min (G2)
Number of subjects: 8
Study 22004512 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion at 4 kcal/min (G4)
Number of subjects: 8
Study 22004512 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion at 1 kcal/min (G1)
Number of subjects: 8
Study 22004512 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 8
Study 22004512 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion
Number of subjects: 8
Study 19223626 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP-420 (100-1200 mg)
Number of subjects: 40
Study 19223626 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP-420 (400 mg)
Number of subjects: 40
Study 19223626 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP-420
Number of subjects: 40
Study 19223626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17961376 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective‐adrenoceptor antagonists (terazosin, doxazosin, tamsulosin, naftopidil)
Number of subjects: 906
Study 17961376 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 alpha‐reductase inhibitors (finasteride, epristeride)
Number of subjects: 906
Study 17961376 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural product (cernilton)
Number of subjects: 906
Study 17961376 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 906
Study 17961376 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil
Number of subjects: 906
Study 16307631 — intervention group
Group type: EXPERIMENTAL
Intervention: Case version A (with clues to suggest limited patient literacy skills)
Number of subjects: 98
Study 16307631 — intervention group
Group type: COMPARATOR
Intervention: Case version B (without clues to suggest limited patient literacy skills)
Number of subjects: 98
Study 16307631 — intervention group
Group type: EXPERIMENTAL
Intervention: General educational strategies recommended for preventing readmission
Number of subjects: 98
Study 12486870 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1000 mg elemental calcium per day for 2 months)
Number of subjects: 15
Study 9655592 — intervention group
Group type: EXPERIMENTAL
Intervention: Field-dependent teaching approach
Number of subjects: 42
Study 9655592 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination teaching approach
Number of subjects: 42
Study 9655592 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall student satisfaction
Number of subjects: 42
Study 7864689 — intervention group
Group type: EXPERIMENTAL
Intervention: disease modifying antirheumatic drug therapy
Number of subjects: 190
Study 2700102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at night
Number of subjects: 25
Study 2700102 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 25
Study 1093613 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified computer-aided diagnosis system
Number of subjects: 0
Study 1093613 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of computer feedback
Number of subjects: 0
Study 31154811 — intervention group
Group type: EXPERIMENTAL
Intervention: Vialogues intervention (12-monthly HIV/STI prevention educational sessions)
Number of subjects: 76
Study 31154811 — intervention group
Group type: EXPERIMENTAL
Intervention: Vialogues intervention
Number of subjects: 76
Study 31109343 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring and feedback system for staff behaviour during surgical procedures
Number of subjects: 9945
Study 31109343 — intervention group
Group type: COMPARATOR
Intervention: Control group (blinded to monitoring data and quality improvement approaches)
Number of subjects: 9945
Study 27865566 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher phosphorus intake for 3 weeks
Number of subjects: 31
Study 27865566 — intervention group
Group type: COMPARATOR
Intervention: Lower phosphorus intake for 3 weeks
Number of subjects: 31
Study 25582031 — intervention group
Group type: COMPARATOR
Intervention: Smiths Medical Jelco (human use) catheter
Number of subjects: 69
Study 25582031 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott Animal Health catheter (veterinary use)
Number of subjects: 69
Study 22902362 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide plus Zoledronic Acid (Thal/ZLD)
Number of subjects: 68
Study 22902362 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic Acid alone (ZLD)
Number of subjects: 68
Study 21848879 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 12
Study 21848879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19219847 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 0
Study 19219847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16919322 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumpstart, a motivationally tailored, print based intervention (n = 95)
Number of subjects: 280
Study 16919322 — intervention group
Group type: COMPARATOR
Intervention: Choose to Move, a self‐help printed booklet (n = 93)
Number of subjects: 280
Study 16919322 — intervention group
Group type: COMPARATOR
Intervention: Wellness, women's health materials (n = 92)
Number of subjects: 280
Study 15309445 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release vitamin C (2 x 250 mg daily) with vitamin E (2 x 91 mg)
Number of subjects: 0
Study 15309445 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain release vitamin C (2 x 250 mg daily) with vitamin E (2 x 91 mg)
Number of subjects: 0
Study 15309445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15079004 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal 600 mg daily
Number of subjects: 431
Study 15079004 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 325 mg daily
Number of subjects: 431
Study 10512212 — intervention group
Group type: EXPERIMENTAL
Intervention: Early controlled range of motion training using an Air‐Cast ankle brace (Group B)
Number of subjects: 30
Study 10512212 — intervention group
Group type: COMPARATOR
Intervention: Cast immobilization in a below‐knee plaster for 6 weeks (Group A)
Number of subjects: 30
Study 8529078 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild exercise
Number of subjects: 0
Study 2318105 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate low-fat diet (60% CHO, 20% fat)
Number of subjects: 8
Study 2318105 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate high-fat diet (40% CHO, 40% fat)
Number of subjects: 8
Study 419761 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexestrol treatment for 12 months or longer
Number of subjects: 176
Study 419761 — intervention group
Group type: COMPARATOR
Intervention: Control group (179 women)
Number of subjects: 176
Study 30991824 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation regarding 'forgetfulness' and screening for cognitive impairment
Number of subjects: 18
Study 27167152 — intervention group
Group type: EXPERIMENTAL
Intervention: CRC screening invitation
Number of subjects: 10271
Study 27167152 — intervention group
Group type: COMPARATOR
Intervention: Control group (not invited for CRC screening)
Number of subjects: 10271
Study 27167152 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors (gender)
Number of subjects: 10271
Study 27167152 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors (education level)
Number of subjects: 10271
Study 26088721 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl iontophoretic transdermal system (ITS) 40 μg/dose
Number of subjects: 604
Study 26088721 — intervention group
Group type: COMPARATOR
Intervention: Morphine intravenous (i.v.) patient-controlled analgesia (PCA) 1 mg/dose
Number of subjects: 604
Study 24997439 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-lesson clinician-guided iCBT program
Number of subjects: 99
Study 24997439 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 99
Study 22234398 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive knee rotation (flexion and extension)
Number of subjects: 0
Study 22234398 — intervention group
Group type: COMPARATOR
Intervention: Static knee position at 10°
Number of subjects: 0
Study 19912069 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PR oxycodone/naloxone
Number of subjects: 985
Study 19912069 — intervention group
Group type: COMPARATOR
Intervention: Oral PR oxycodone
Number of subjects: 985
Study 19912069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 985
Study 17893165 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum BB536 powder
Number of subjects: 44
Study 17893165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 15034826 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin (20 mg/kg per day; maximum dose, 1000 mg/day) for 5 days
Number of subjects: 149
Study 15034826 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftriaxone (75 mg/day; maximum dose, 2.5 g/day) for 5 days
Number of subjects: 149
Study 15034826 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin
Number of subjects: 149
Study 15034826 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftriaxone
Number of subjects: 149
Study 12118266 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg/day)
Number of subjects: 61
Study 12118266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 9428871 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasless, retractor group
Number of subjects: 26
Study 9428871 — intervention group
Group type: COMPARATOR
Intervention: Conventional CO2 pneumoperitoneum group (CPP)
Number of subjects: 26
Study 8087385 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry-powder inhaler (Turbuhaler)
Number of subjects: 9
Study 8087385 — intervention group
Group type: COMPARATOR
Intervention: Pressurized aerosol (aerosol device)
Number of subjects: 9
Study 2571502 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic reaction times in acute schizophrenics
Number of subjects: 47
Study 2571502 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic reaction times in remitted schizophrenics
Number of subjects: 47
Study 2571502 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal volunteers)
Number of subjects: 47
Study 31092706 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural waveform analysis through the needle (EWA-N)
Number of subjects: 120
Study 31092706 — intervention group
Group type: COMPARATOR
Intervention: Epidural waveform analysis through the catheter (EWA-C)
Number of subjects: 120
Study 28620779 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored DXA result letter and educational bone health brochure
Number of subjects: 7749
Study 28620779 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 7749
Study 25306213 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental limits on TV viewing time
Number of subjects: 816
Study 25306213 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental limits on TV programming content
Number of subjects: 816
Study 25799808 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (40 mg/kg/day) for 7 days
Number of subjects: 204
Study 25799808 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 204
Study 22851554 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 3 mg/m² on day 1 of course one of therapy
Number of subjects: 1115
Study 22851554 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GO)
Number of subjects: 1115
Study 22851554 — intervention group
Group type: COMPARATOR
Intervention: Meta-analysis of 2,228 patients in two UK trials
Number of subjects: 1115